tickrz reports
tickrz rank
C
Johnson & Johnson (JNJ)
Healthcare | Drugs
135.45  0.69%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankC / 280Warren Buffett RankA / 70
Pure Value RankC / 348Dividend RankA / 58
Moat RankA / 41Financial Strength RankA / 36
Growth RankB / 225Momentum RankC / 261
JNJ vs DRUGS SECTOR & S&P 500
VALUATION
JNJSECTORS&P 500
P/E RATIO22.5635.719.28
EV/EBITDA RATIO16.0425.111.77
P/S RATIO5.087.12.03
P/B RATIO5.128.73.09
QUALITY
RETURN ON EQUITY22.63%16.98%13.82%
RETURN ON CAPITAL22.66%26.23%10.04%
NET MARGIN22.99%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.44%
PAYOUT RATIO53.8%
3 YR DIVIDEND GROWTH6.74%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY48%
INTEREST COVERAGE24.68x
CURRENT RATIO1.34
GROWTH
5 YR EPS GROWTH11.18%
5 YR SPS GROWTH2.04%
5 YR BPS GROWTH4.43%
About tickrz
Key Concepts
Great Investors
Johnson & Johnson has carved out a durable competitive advantage within its industry
tickrz rank C / 280
Johnson & Johnson receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking C / 348Warren Buffett ranking A / 70
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Johnson & Johnson's valuation score is comprised of a P/E ratio of 22.6x, a P/B ratio of 5.1x, a P/S ratio of 5.1x, and an EV/EBITDA ratio of 16x. Johnson & Johnson ranks 348 out of the S&P 500 constituents on valuation--a relatively weak score.Johnson & Johnson ranks 70 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Johnson & Johnson warrants further investigation.

quality
moat A / 41financial strength A / 36
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Johnson & Johnson appears to have a durable competitive advantage within the Healthcare sector. Johnson & Johnson has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 24.68x, a debt/equity ratio of 48% and a Moat Rank of 41 translate to a strong Financial Strength score.


momentum C / 261
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 12.43% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 261. Based on its 12 month stock performance, Johnson & Johnson will not appeal to momentum investors.

yield A / 58
value + yield
Shares currently yield 2.44%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Johnson & Johnson ranks 58 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate Johnson & Johnson.

growth B / 225
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 11.2% 5 year annualized EPS growth, 2% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 4.4% combine to produce this average score.

Johnson & Johnson (JNJ)
Healthcare | Drugs
135.45  0.69%


tickrz rank
C
VALUATION RATIOS
P/E Ratio22.56x
P/B Ratio5.12x
P/S Ratio5.08x
EV/EBITDA Ratio16.04x
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.44%
PAYOUT RATIO53.8%
3 YR DIVIDEND GROWTH6.74%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY48%
INTEREST COVERAGE24.68x
CURRENT RATIO1.34
MOAT
ROE22.63%
ROIC22.66%
Net Margin22.99%
GROWTH
5 YR EPS GROWTH11.18%
5 YR SPS GROWTH2.04%
5 YR BPS GROWTH4.43%

TICKRZ RANK
Johnson & Johnson receives a C ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Johnson & Johnson's valuation score is comprised of a P/E ratio of 22.6x, a P/B ratio of 5.1x, a P/S ratio of 5.1x, and an EV/EBITDA ratio of 16x. Johnson & Johnson ranks 348 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Johnson & Johnson ranks 70 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a strong score, meaning it ranks highly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Johnson & Johnson warrants further investigation.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Johnson & Johnson appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Johnson & Johnson has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 24.68x, a debt/equity ratio of 48% and a Moat Rank of 41 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 12.43% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 261. Based on its 12 month stock performance, Johnson & Johnson will not appeal to momentum investors.

VALUE + YIELD
Shares currently yield 2.44%. Our dividend ranking approach looks at a company's dividend growth rate, payout ratio, business moat, and valuation. Based on our methodology, Johnson & Johnson ranks 58 among the S&P 500 constituents. Investors looking for undervalued dividend stocks will want to closely investigate Johnson & Johnson.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value produce an average score. 11.2% 5 year annualized EPS growth, 2% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 4.4% combine to produce this average score.